Myelodysplastic syndrome

Changed by Francis Deng, 19 Feb 2019

Updates to Article Attributes

Body was changed:

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal haematological stem cell disorders characterized by dysplasia and ineffective hematopoiesis. It has sometimes been referredcarries a risk of transformation to as a preleukaemia or a preleukaemic conditionacute leukemia.

Epidemiology

Its overall incidence is thought to be around 3.3 per 100,000. The incidence in patients older than age 70 is greater ranging between 15 and 50 per 100,000 2.

Pathology

Classification

The French-American-British (FAB) classification is commonly used in the vernacular:

  • refractory anaemia
    • less than 5% primitive blood cells (myeloblasts) in the bone marrow and pathological abnormalities primarily seen in red cell precursors
  • refractory anaemia with ring sideroblasts (RARS)
    • less than 5% myeloblasts in the bone marrow, but distinguished by the presence of 15% or greater red cell precursors in the marrow being abnormal iron-stuffed cells called "ringed sideroblasts"
  • refractory anaemia with excess blasts (RAEB)
    • 5-20% myeloblasts in the marrow
  • refractory anemia with excess blasts in transformation (RAEB-T)
  • chronic myelomonocytic leukaemia (CMML), not to be confused with chronic myelogenous leukaemia (CML)
    • less than 20% myeloblasts in the bone marrow and greater than 1*109/L monocytes in peripheral blood

The World Health Organisation classification was built upon the FAB system:

  • MDS with single lineage dysplasia
    • includes refractory anemia, refractory neutropenia, and refractory thrombocytopenia
  • MDS with multilineage dysplasia (most common type)
  • MDS with ring sideroblasts
    • MDS with ring sideroblasts and single lineage dysplasia
    • MDS with ring sideroblasts and multilineage dysplasia
  • MDS with excess blasts (second most common type)
  • MDS with isolated del(5q)
  • MDS, unclassifiable
  • childhood MDS
    • refractory cytopenia of childhood (most common type of childhood MDS)

Radiographic features

CT 

May show increased areas of sclerosis affecting portions of the skeleton representing osteomyelosclerosis.

MRI

Signal characteristics (albeit non-specific for MDS) in affected marrow include 5:

  • T1: low signal
  • T2: high signal

There is usually a homogeneous pattern of disease within the marrow.

Treatment and prognosis

The course of the disease is chronic and irreversible. Allogeneic stem cell transplantation (ASCT) remains the only curative treatment, although only a minority of patients may be eligible.

Complications

See also

  • -<p><strong>Myelodysplastic syndromes (MDS)</strong> are a heterogeneous group of clonal haematological stem cell disorders. It has sometimes been referred to as a preleukaemia or a preleukaemic condition.</p><h4>Epidemiology</h4><p>Its overall incidence is thought to be around 3.3 per 100,000. The incidence in patients older than age 70 is greater ranging between 15 and 50 per 100,000 <sup>2</sup>.</p><h4>Pathology</h4><h5>Classification</h5><p>The <strong>French-American-British (FAB) classification</strong> is commonly used:</p><ul>
  • +<p><strong>Myelodysplastic syndromes (MDS)</strong> are a heterogeneous group of clonal haematological stem cell disorders characterized by dysplasia and ineffective hematopoiesis. It carries a risk of transformation to acute leukemia.</p><h4>Epidemiology</h4><p>Its overall incidence is thought to be around 3.3 per 100,000. The incidence in patients older than age 70 is greater ranging between 15 and 50 per 100,000 <sup>2</sup>.</p><h4>Pathology</h4><h5>Classification</h5><p>The French-American-British (FAB) classification is commonly used in the vernacular:</p><ul>
  • -<a href="/articles/chronic-myelomonocytic-leukaemia">chronic myelomonocytic leukaemia</a> (CMML), not to be confused with chronic myelogenous leukaemia (CML)<ul><li>less than 20% myeloblasts in the bone marrow and greater than 1*10<sup>9</sup>/L monocytes in peripheral blood</li></ul>
  • +<a href="/articles/chronic-myelomonocytic-leukaemia">chronic myelomonocytic leukaemia</a> (CMML)<ul><li>less than 20% myeloblasts in the bone marrow and greater than 1*10<sup>9</sup>/L monocytes in peripheral blood</li></ul>
  • +</li>
  • +</ul><p>The <a title="World Health Organisation classification of tumours of haematopoietic and lymphoid tissues" href="/articles/who-classification-of-tumours-of-haematopoietic-and-lymphoid-tissues-1">World Health Organisation classification</a> was built upon the FAB system:</p><ul>
  • +<li>MDS with single lineage dysplasia<ul><li>includes refractory anemia, refractory neutropenia, and refractory thrombocytopenia</li></ul>
  • +</li>
  • +<li>MDS with multilineage dysplasia (most common type)</li>
  • +<li>MDS with ring sideroblasts<ul>
  • +<li>MDS with ring sideroblasts and single lineage dysplasia</li>
  • +<li>MDS with ring sideroblasts and multilineage dysplasia</li>
  • +</ul>
  • +</li>
  • +<li>MDS with excess blasts (second most common type)</li>
  • +<li>MDS with isolated del(5q)</li>
  • +<li>MDS, unclassifiable</li>
  • +<li>childhood MDS<ul><li>refractory cytopenia of childhood (most common type of childhood MDS)</li></ul>
  • -<li><a title="Sideroblastic anaemia" href="/articles/sideroblastic-anaemia">sideroblastic anaemia</a></li>
  • +<li><a href="/articles/sideroblastic-anaemia">sideroblastic anaemia</a></li>
  • +<li><a title="WHO classification of tumours of haematopoietic and lymphoid tissues" href="/articles/who-classification-of-tumours-of-haematopoietic-and-lymphoid-tissues-1">WHO classification of tumours of haematopoietic and lymphoid tissues</a></li>

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.